Technical Analysis for NEVPF - Neurovive Pharm Ab Ord

Grade Last Price % Change Price Change
grade B 0.21 0.00% 0.0000
NEVPF closed unchanged on Friday, August 23, 2019, on 74 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical NEVPF trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Wide Range Bar Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%

Older signals for NEVPF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in Phase II clinical study for the treatment of traumatic brain injuries; and ToxPhos for the mitochondrial toxicity test. The company is also developing NVP015 for mitochondrial genetic disorders; NVP025 mitochondrial myopathies program; NV556 for the treatment of mitochondrial myopathy; NVP022 for targeting mitochondrial metabolic pathways in non-alcoholic steatohepatitis (NASH) and complementing NV556 in the treatment of NASH; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea, as well as agreements with Fresenius Kabi. The company also has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in mitochondrial medicine field. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.
Medical Specialties Organ Systems Hepatocellular Carcinoma Sanofi Steatohepatitis Traumatic Brain Injuries Sihuan Pharmaceutical
Is NEVPF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.6688
52 Week Low 0.0988
Average Volume 2,826
200-Day Moving Average 0.2779
50-Day Moving Average 0.1854
20-Day Moving Average 0.2376
10-Day Moving Average 0.2209
Average True Range 0.0209
ADX 20.81
+DI 21.9596
-DI 52.7578
Chandelier Exit (Long, 3 ATRs ) 0.2473
Chandelier Exit (Short, 3 ATRs ) 0.2089
Upper Bollinger Band 0.2878
Lower Bollinger Band 0.1874
Percent B (%b) 0.23
BandWidth 42.255892
MACD Line 0.0067
MACD Signal Line 0.0137
MACD Histogram -0.007
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.3057
Resistance 3 (R3) 0.2951 0.2525 0.2898
Resistance 2 (R2) 0.2525 0.2282 0.2579 0.2844
Resistance 1 (R1) 0.2313 0.2131 0.2419 0.2419 0.2791
Pivot Point 0.1887 0.1887 0.1941 0.1941 0.1887
Support 1 (S1) 0.1675 0.1644 0.1781 0.1781 0.1409
Support 2 (S2) 0.1249 0.1493 0.1303 0.1356
Support 3 (S3) 0.1037 0.1249 0.1303
Support 4 (S4) 0.1143